S Ruíz García

CANNABIDIOL EN PACIENTES CON EPILEPSIA REFRACTARIA: SEGURIDAD Y GRADO DE SATISFACCIÓN

José M. Serra López-Matencio, Esther Ramírez Herráiz, María Pérez Abánades, A Calvo Garcia et autres

17 al 19 de Octubre del 2024. 70 Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria(SEFH). Participa en el evento científico por excelencia en el marco de la Farmacia Hospitalaria en España.

4CPS-189 Local experience on the use of cannabidiol for the treatment of refractory epilepsy: safety and efficacy on a 10 patient cohort

JM Serra López-Matencio, A Alvarez Yuste, Esther Ramírez Herráiz, A Calvo Garcia et autres

Background and Importance Cannabidiol is approved in Europe as adjunctive therapy for preventing seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS), and Tuberous Sclerosis Complex (TSC) in patients with previous treatment refractory epilepsy. Aim and Objectives This study aims to evaluate …

es (code pays fourni par la source)

4CPS-250 Home delivery for outpatients with immune-mediated diseases: experience and patient satisfaction

S Ruíz García, Esther Ramírez Herráiz, A Calvo Garcia, María Pérez Abánades et autres

Background and importance Patients with immune-mediated diseases (IMIDs) frequently need therapies from the hospital pharmacy. Due to the COVID-19 pandemic, a home delivery service (HDS) with telepharmacy follow-up was started to avoid unnecessary visits to hospital. Aim and objectives To describe the …

es (code pays fourni par la source)

Detection of SARS-CoV-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients

Diego Aníbal Rodríguez-Serrano, Emilia Roy‐Vallejo, Nelly Daniela Zurita Cruz, Alexandra Martín Ramírez et autres

Abstract COVID-19 has overloaded national health services worldwide. Thus, early identification of patients at risk of poor outcomes is critical. Our objective was to analyse SARS-CoV-2 RNA detection in serum as a severity biomarker in COVID-19. Retrospective observational study including 193 patients …

es (code pays fourni par la source)

P.509 Centenary Psychosis

Isabel Pinto, S Ruíz García, Cláudia Pereira, Inês Morais Caldas et autres

IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study

José María Galván‐Román, S. C. Rodriguez-García, Emilia Roy‐Vallejo, Ana Marcos‐Jiménez et autres

es, gb (code pays fourni par la source)

5PSQ-098 Allergies and intolerances: an opportunity for improvement

MD Ibáñez Zurriaga, S Ruíz García, Esther Ramírez Herráiz, A Garcia Peralo et autres

Background and importance In 2014, the Institute of Safe Medication Practice published a bulletin that showed the importance of drug hypersensitivity reactions. Pharmacy services could contribute to identify and avoid allergic reactions in patients. Aim and objectives To evaluate the allergies and …

es (code pays fourni par la source)

1ISG-023 Cystic fibrosis outpatient treatment costs: a retrospective analysis

A Calvo García, MD Ibáñez Zurriaga, Ana Sánchez Azofra, S Ruíz García et autres

Background Cystic fibrosis (CF) is the most serious and frequent hereditary autosomal disease that causes respiratory, hepatic and pancreatic dysfunction. Purpose To assess the pharmaceutical cost associated with CF outpatients from the Adult Cystic Fibrosis Unit at a third-level hospital. Material and …

es (code pays fourni par la source)

5PSQ-013 Prescriptions of direct oral anticoagulants in patients admitted

S Ruíz García, E Alañón Plaza, A Calvo García, I Cidoncha Muñoz et autres

Background Direct oral anticoagulants (DOACs) require different follow-up than vitamin K inhibitors. DOACs dose adjustment depends on indication, age, renal function and weight, which could made dosage errors easier. Purpose To analyse the use of DOACs and their prescription profile in the …

es (code pays fourni par la source)

5PSQ-077 Cost-effectiveness of biosimilar etanercept in clinical practice use

S Ruíz García, Esther Ramírez Herráiz, A Calvo García, Concepción Nieto et autres

Background Etanercept is a tumour necrosis factor (TNF) inhibitor indicated for active rheumatoid arthritis (RA) as monotherapy or in combination with methotrexate. Biosimilar drugs currently commercialised are Benepali and Erelzi. Purpose To evaluate biosimilar etanercept effectiveness in patients with RA and calculate …

es (code pays fourni par la source)

Extended OECD 422 screening study for the evaluation of substances with suspected reproductive toxicity and/or endocrine activity

Lawrence Segal, Lourdes Canut, David Myers, S Ruíz García et autres

gb, us (code pays fourni par la source)

Safety evaluation of a natural extract rich in functional lipids (F1110), following 90 day oral gavage administration in the Wistar rat

Anna Torrent, E. Montell, Josep Vergés, S Ruíz García et autres

es (code pays fourni par la source)